Literature DB >> 35983423

An Introduction to Tirzepatide.

Taylor Bertsch1.   

Abstract

Entities:  

Year:  2022        PMID： 35983423      PMCID： PMC9331617          DOI： 10.2337/cd22-0038

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


× No keyword cloud information.
  8 in total

1.  Tirzepatide and the new era of twincretins for diabetes.

Authors:  Tricia M-M Tan; Bernard Khoo
Journal:  Lancet       Date:  2021-06-27       Impact factor: 79.321

2.  The effectiveness and value of tirzepatide for type 2 diabetes mellitus.

Authors:  Dmitriy Nikitin; Grace A Lin; Jon D Campbell; Ryan N Hansen; Elizabeth Brouwer; Yilin Chen; Serina Herron-Smith; Foluso Agboola; Steven D Pearson
Journal:  J Manag Care Spec Pharm       Date:  2022-06

3.  Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

Authors:  Stefano Del Prato; Steven E Kahn; Imre Pavo; Govinda J Weerakkody; Zhengyu Yang; John Doupis; Diego Aizenberg; Alan G Wynne; Jeffrey S Riesmeyer; Robert J Heine; Russell J Wiese
Journal:  Lancet       Date:  2021-10-18       Impact factor: 79.321

4.  Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.

Authors:  Dominik Dahl; Yukiko Onishi; Paul Norwood; Ruth Huh; Ross Bray; Hiren Patel; Ángel Rodríguez
Journal:  JAMA       Date:  2022-02-08       Impact factor: 157.335

5.  Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.

Authors:  Julio Rosenstock; Carol Wysham; Juan P Frías; Shizuka Kaneko; Clare J Lee; Laura Fernández Landó; Huzhang Mao; Xuewei Cui; Chrisanthi A Karanikas; Vivian T Thieu
Journal:  Lancet       Date:  2021-06-27       Impact factor: 79.321

Review 6.  The Role of Incretins on Insulin Function and Glucose Homeostasis.

Authors:  Jens Juul Holst; Lærke Smidt Gasbjerg; Mette Marie Rosenkilde
Journal:  Endocrinology       Date:  2021-07-01       Impact factor: 4.736

7.  LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.

Authors:  Tamer Coskun; Kyle W Sloop; Corina Loghin; Jorge Alsina-Fernandez; Shweta Urva; Krister B Bokvist; Xuewei Cui; Daniel A Briere; Over Cabrera; William C Roell; Uma Kuchibhotla; Julie S Moyers; Charles T Benson; Ruth E Gimeno; David A D'Alessio; Axel Haupt
Journal:  Mol Metab       Date:  2018-10-03       Impact factor: 7.422

8.  Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

Authors:  Juan P Frías; Melanie J Davies; Julio Rosenstock; Federico C Pérez Manghi; Laura Fernández Landó; Brandon K Bergman; Bing Liu; Xuewei Cui; Katelyn Brown
Journal:  N Engl J Med       Date:  2021-06-25       Impact factor: 91.245
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.